BASEL, Switzerland, April 13, 2026
Roche has announced that its Elecsys® Neurofilament Light Chain (NfL) blood test has received CE mark approval for detecting neuroinflammation in patients with relapsing-remitting multiple sclerosis (RRMS). This milestone represents a significant advancement in multiple sclerosis (MS) disease monitoring, offering a minimally invasive, accessible alternative to traditional diagnostic methods such as MRI scans. The approval highlights Roche’s continued leadership in innovative diagnostics aimed at improving neurological disease management and patient outcomes.
Minimally Invasive Innovation for MS Monitoring
The newly approved Elecsys NfL test is designed to measure Neurofilament Light Chain (NfL), a key biomarker released during neuroaxonal damage, providing clinicians with real-time insight into neuroinflammatory activity in MS patients. Unlike conventional monitoring approaches that rely heavily on magnetic resonance imaging (MRI), this simple blood-based test enables easier, faster, and more frequent assessment of disease progression.
This innovation is particularly significant for patients who face barriers to regular MRI access, including geographic, financial, or logistical challenges. By requiring only a standard blood sample, the test allows for local sample collection and broader patient access, making routine monitoring more practical. The ability to track underlying biological disease activity rather than relying solely on imaging represents a paradigm shift in MS care, enabling clinicians to detect changes earlier and adjust treatment strategies more effectively.
Enhancing Clinical Decision-Making in Multiple Sclerosis
Advertisement
Multiple sclerosis affects over 2.9 million people worldwide, and early detection of disease activity is critical for optimising treatment outcomes and preventing long-term disability. The Elecsys NfL test provides quantitative measurement of neuroaxonal injury, offering a complementary tool to clinical assessments and imaging techniques.
By delivering standardised and consistent results across Roche’s widely available cobas diagnostic platforms, the test ensures reliable and reproducible data regardless of testing location. Elevated levels of NfL in blood are associated with ongoing nerve damage and neuroinflammation, allowing healthcare providers to identify disease activity earlier and intervene promptly. This capability supports more personalised treatment strategies, helping clinicians tailor therapies based on individual patient disease dynamics.
The CE mark approval follows the test’s recognition with Breakthrough Device Designation from the U.S. Food and Drug Administration, further validating its clinical potential and innovation. With increasing emphasis on precision medicine, tools like Elecsys NfL are expected to play a crucial role in transforming how chronic neurological diseases are monitored and managed.
Expanding Access and Transforming Neurology Diagnostics
The introduction of a blood-based biomarker test for neuroinflammation marks a major step forward in neurology diagnostics, where non-invasive and scalable solutions are urgently needed. Roche’s Elecsys NfL test addresses this gap by enabling frequent, accessible monitoring without the need for specialised imaging infrastructure, thereby improving healthcare equity and patient convenience.
Beyond multiple sclerosis, NfL is a well-established biomarker associated with various neurological disorders, including neurodegenerative diseases and acute brain injuries. This opens the potential for future applications of the test across a broader spectrum of neurological conditions, further strengthening Roche’s position in the diagnostics innovation landscape.
Roche continues to invest heavily in neurology research and development, with a pipeline of diagnostic tools and therapeutic solutions targeting diseases such as Alzheimer’s, Parkinson’s, and spinal muscular atrophy. By integrating diagnostics, therapeutics, and digital health solutions, the company aims to deliver holistic, patient-centered care models that address complex healthcare challenges.
With CE mark approval now secured, the Elecsys NfL test is expected to see broad adoption across regions accepting CE certification, enabling clinicians worldwide to improve disease monitoring and patient outcomes in multiple sclerosis. This advancement underscores Roche’s commitment to pushing the boundaries of science and technology to transform the future of neurological care.
Source: Roche press release
